ClinicalTrials.gg
Not yet recruitingNCT07152444Updated Sep 3, 2025

A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension

A Phase 1 interventional study of QLS1410 (CYP11B2 inhibitor) and placebo in Uncontrolled Hypertension, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 408 studies in Hypertension with a site in China — 123 open to participants now, 146 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
242nd of 306
78 · median 255
Started
2025
with 46 others
Phase 1
19 of 408
4 open now
Primary completion
2026-05
later than 39 of 145 live
Registered
347th of 408
by date

Among the 408 studies in Hypertension with a site in China, this one is the 242nd largest by planned enrollment of the 306 interventional ones that give a count, is one of 47 that started in 2025, is one of 19 in phase 1, reaches primary completion later than 39 of the 145 other live ones, and was the 347th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

123 of the 408 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 408 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of single and multiple ascending doses of QLS1410 in healthy Chinese adults and participants with mild essential hypertension

Read the detailed description

This study consists of three parts, as follows:

Part A is a randomized, placebo-controlled, double-blind single ascending dose (SAD) study in healthy Chinese adults, consisting of 5 cohorts. Starting dose of 0.5 mg by oral administration are planned. Once sufficient safety and PK data are obtained from the SAD cohorts, the SMC will determine the dosage of initial cohort in Part B and Part C.

Part B is a randomized, open-label, two-cycle, crossover food effect (FE) study under fasting and fed (high-fat meal) conditions.

Part C is a randomized, placebo-controlled, double-blind multiple ascending doses (MAD) study in participants with mild essential hypertension, consisting of 3 cohorts.

03

Conditions studied

  • Uncontrolled Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part A \& Part B: Healthy Participants
  • Able to understand and willing to comply with all study visits, procedures, restrictions and provide the written form (ICF).
  • Males and females aged 18 to 55 years, inclusive.
  • Weight ≥ 50 kg for males and ≥ 45 kg for females, (BMI) between 18 and 26 kg/m\^2, inclusive, at screening.
  • Has a mean seated office systolic blood pressure (SBP) 110\~139 mmHg (inclusive) and diastolic blood pressure (DBP) 70\~89 mmHg (inclusive) at screening and baseline; measured 3 times consecutively (1-2 min intervals).
  • (QT corrected using Fridericia's formula) \<450 ms for males and \<470 ms for females.
  • Participants (including partners) must agree to abstain from sperm/egg donation and pregnancy plans, and to use highly effective , from signing the ICF until 3 months after receiving the last dose of product.
  • Part C: Participants with Mild Essential Hypertension
  • Able to understand and willing to comply with all study visits, procedures, restrictions and provide the ICF.
  • Males and females aged 18 to 65 years (18 to 65 years in MAD study), inclusive.
  • Weight ≥ 50 kg for males and ≥ 45 kg for females, BMI between 18 and 28 kg/m\^2, inclusive, at screening.
  • Has a mean seated office SBP 140\~159 mmHg (inclusive) and DBP 85\~99 mmHg (inclusive) at screening and baseline; measured 3 times consecutively (1-2 min intervals).
  • QTcF \<450 ms for males and \<470 ms for females.
  • No use of antihypertensive medications (including ACEIs, ARBs, CCBs, ARNIs, diuretics, etc.) within 30 days prior to signing the ICF.
  • Participants (including partners) must agree to abstain from sperm/egg donation and pregnancy plans, and to use highly effective contraception, from signing the ICF until 3 months after receiving the last dose of investigational product.

Exclusion criteria

Exclusion Criteria:

  • Part A \& Part B: Healthy Participants
  • Any medical condition/disease at screening deemed by the investigator to require exclusion, including but not limited to the nervous, psychiatric, cardiovascular, hematologic/lymphatic, immune, respiratory, digestive, urinary, metabolic and skeletal systems.
  • Dysphagia or any surgical condition/disease that may affect drug absorption, distribution, metabolism, or excretion, at screening.
  • Use of systemic within 3 months prior to screening.
  • Mean pulse/heart rate (HR) >100 or \<50 bpm after ≥5 min of rest at screening (measured 3 times consecutively).
  • Any laboratory abnormalities that meet the test requirements should be noted during screening (if necessary, retest can be conducted at least one week apart):
  • Smoking >5 cigarettes/day on average within 6 months before screening, or current use of e-cigarettes.
  • Alcohol consumption >14 units/week (1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine) within 6 months before screening, or has a positive breath alcohol test at screening.
  • Blood donation >400 mL within 3 months or >200 mL within 4 weeks before screening, or plan to donate blood during the study.
  • Use of strong or CYP1A2 inhibitors within 7 days or 5 half-lives (whichever is longer) before screening. Use of strong CYP3A4 inducer within 14 days or 5 half-lives (whichever is longer) before screening.
  • Use of any prescription drugs, OTC drugs, traditional medicines, and dietary supplements within 2 weeks or 5 half-lives (whichever is longer) prior to randomization.
  • Pregnant/lactating females or positive pregnancy test at screening.
  • Inability to tolerate a high-fat meal (for Part B only).

Part C: Participants with Mild Essential Hypertension

  • Secondary hypertension.
  • Orthostatic tachycardia or hypotension at screening, or history of related symptoms (e.g., dizziness, weakness, blurred vision upon standing).
  • History of syncope.
  • Metabolic/cardiovascular disorders: 1) Diabetes (fasting glucose ≥7.0 mmol/L [126 mg/dL] or ≥6.5%); 2) History of cardiovascular events (e.g., stroke, , myocardial infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary intervention, heart failure hospitalization) or valvular disease; 3) Personal/family history of long syndrome, torsades de pointes (TdP), arrhythmias, or sudden cardiac death; 4) Other conditions that may interfere with the study or increase risk, per investigator judgment.
  • Laboratory abnormalities (as defined in Part A/B, with repeat testing allowed).
  • Any other condition deemed unsuitable by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    QLS1410

    Part A: Healthy adults will be randomized (6:2) to receive a single dose (1.5 mg \~ 20 mg) of QLS1410 or placebo,especially, the starting dose will be 0.5 mg of QLs1410 Part B: QLS1410 will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 14 days. The dose of QLS1410 or placebo is based on upcoming data from SAD part. Part C: Hypertensive participants will be randomized (8:2) to receive QLS1410 or placebo QD for 14 continuous days. The starting dose of QLS1410 or placebo is based on upcoming data from SAD part.

    Drug: QLS1410 (CYP11B2 inhibitor)

  • Placebo comparator
    Placebo

    Part A: Healthy adults will be randomized (6:2) to receive a single dose (1.5 mg \~ 20 mg) of QLS1410 or placebo Part B: QLS1410 will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 14 days. The dose of QLS1410 or placebo is based on upcoming data from SAD part. Part C: Hypertensive participants will be randomized (8:2) to receive QLS1410 or placebo QD for 14 continuous days. The starting dose of QLS1410 or placebo is based on upcoming data from SAD part.

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment emergent Adverse Events as assessed by CTCAE v5.0

    Time frame: up to approximately 1 month

Secondary outcomes

  1. Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)]

    Time frame: up to approximately 1 month

  2. Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)]

    Time frame: up to approximately 1 month

  3. Maximum observed plasma concentration (Cmax)

    Time frame: up to approximately 1 month

  4. Terminal elimination half-life (t1/2)

    Time frame: up to approximately 1 month

  5. Apparent clearance (CL/F)

    Time frame: up to approximately 1 month

  6. Apparent volume of distribution (Vz/F)

    Time frame: up to approximately 1 month

  7. Mean residence time (MRT)

    Time frame: up to approximately 1 month

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for May 2026, 8 months later.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 8 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 3, 2025
StartEst.
Sep 2025
Primary completionEst.
May 2026
CompletionEst.
Jul 2026
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07152444
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Sep 2025 (estimated)
Primary completion
May 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Sep 3, 2025

Study contacts

Haiyan Li, B.M
Contact
haiyanli1027@hotmail.com
18600489179
Cheng Cui, M.D
Contact
cuicheng1226@163.com
13011825605

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLS1410

Start the discussion